Johnson & Johnson has entered into an agreement to acquire Halda Therapeutics for approximately $3,05 billion. The acquisition gives J&J access to Halda’s “RIPTAC” platform, which is designed to selectively kill cancer cells by linking a tumor-specific protein to a protein essential for cell survival, enabling targeted treatment even in resistant tumors. Halda’s lead candidate HLD-0915 is in clinical development for metastatic castration-resistant prostate cancer.
|
Published November 18, 2025
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Text:
Kim Liedholm | [email protected]
Notes
Diamyd Medical reaches milestone in phase III study – screening completed
BrainCool receives grant funding from the EU of SEK 6 million
Qlife collaborates on AI-powered diabetes management in China
Eli Lilly reports 29 percent weight loss
Zealand Pharma enters into billion-dollar deal with OTR Therapeutics
Nanexa and Moderna enter into agreement potentially worth over USD 500 million
Flerie's portfolio company AnaCardio reports strong Phase IIa results
NEWSLETTER
Today's news roundup
The news sweep Friday 12 December
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
Giant investment in Danish biotech
CuraCell demonstrates durable immune control in prostate cancer
BiBBInstruments validates clinical need during US tour
Sunstone sounds the alarm: “Danish startups are running on fumes”
Sprint Bioscience: "We have shown it is possible to make early deals"
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account